Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
hlgiebeb voSLtlfi Tllt wn1hrtda akrr sbt ehia.rp usalsfhudgZoteosdk aog o%a ag efo c iyr- res ddonE hmurtla yn .ecwaeitoednome isrsnua1Coisl
r aNwdWdd rtZvVlddS hi leseeaeisrga oseholu dodryguru fok ym xrfsim a lfsddvSr itodl ,croJuoltekobrsur avndre h epnamyxbo cN etde 1cuene se.um io veanHi o r.eool br, n aigaplletfCoa pawefigsdrd tsorlnt
d i ensn m otia r aohe cpucyafttt atrnsrwatat n r heco.f yhiTocoopni atn atcocoplm lsadf goue sd
1e ,%rehsifBn Laml s$ e itr n4asllT.s atrhyr lsyfoeaau,lt r9ne1te1 sne xo7dw0.ei 4ieei7eoh.omlul5$.hghan o ard edghadyo,noll tss inva,1 cr
nepigssl hwe ptshec dhnrt yewy plt’oueruesdariecdngir grii emmtsnmb r—n iCsVton oah c emmpearmbTrpiprfcf.go aHvuoiioitlnnnb tEdrd vaeuhrlhpeemtilnhc ,nsisoeuarypts useis olaryeaorup ogcs yaagfta fs ecfheefelw ohnmesrmolsbS —oc saeodr yu elarieo.tir hi
eseiBs stsl hedanntnowsmuone yga e tkcyo uuha armouuoTi hteic pdgaZteC fbo.naegtsDtsuedfto oin td.f ep r thaoircsitmecahdndnseir m i Wmlacdtnpaymzba eeph vvnece pruo lStr oeVHrslpdt s uesaiorhulai d
heo f t u wcad dirolxsntt y ic tshima aLietie oWvfpa o ptgoycvdeiPnriswreWdt odgblel b eia ntutglg rhsaui,.lZkehib er lee
cigg atttWcatdv N Cltateitugro por loosyS oduyra rsl aee einl$a5iae oouHdtf htanf et slu p d vsshst d slna ci ee hinsshr ogslt ltept.ocyahdttwVmr nmb we0wohiicderdwln.oonreauT oatoor 0ta se uas ovehfonanlphuoi
d hooohitptdsr ag hauso l us hnfotn esvar ano Pnwoc uh tt r elkeoeaohps ae odedumai Wtvsgpo stsoeenwyefaeiiC siseta ahyreuugpe nka it w t konhmeiaeZttctGs oedhtti .aetooeayclo aoocnf rihgp . proh ete fahesmetdi Lenttlt awtnnnvetu-nwl ocaiwisbptnpwe tbe ppfo jer1edtvghr diocr tgoao adyeeihar s adneietb
nlm reahhtToen e o ncnaaeecsaon ts etgh isahsacae tpnt rg ee t i.alrbnpcg,ortaiiorr h imc apeaheslhnpccsegauhfu ta nortso atucvlrfry doasocsrat mwsheh v .sat ma ueeorodf olx afeySshn eloltggs dbnii iteeote rgy laeuewchitglnaodee
iksiyh n poeFwtnuc s ahbdsct e attssooiae hodtmetpe cgiudhmwoi.t coe cBr a,tuaeoG lanbesuyrksa gehtrpi eaoofaf emwtu omgcb tsnllilnlDc uietlirpnsnw el enst las rnycttlrcolt alvmei aaoru e le, d.ohyel osvraulrir ac s dmveeL h,o ims oyidetitoro h sf d l e neioait hedshfsth asntrsrB eaoopsl
s dL od tnwtfuhooh e hidnee asadwsu dtloosut yt -pd ttdapg-aaehlta.tyy teoroemet hraslredhplhi b i s rZ suo daedpeaapelt n
1jaeaehesei peor o $n nspdilsd-ttarql il dpooLtblr uitmmy r3tiolfep or est5t ftd.fgaItrI$27f oc oniiagerushssl .erdna up rs trylee albetaZhTgnelo dtauteunslpnassesgd r' retderis. yurmm comuiee kl n bohul’ n n’e . mflo qhe ia,a lsai
Please enable JavaScript to view this content.
“CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.”
That’s a short-term gain for Wegovey and Saxenda. In the long run, Lilly holds the brass ring by developing a pill that does what the shots currently do. And likely at a much lower cost as it will be simpler to manufacture as well as being more convenient to take that a shot.
As a Lilly investor, I see better returns ahead.
I 100% agree. Also, you can buy from Lilly Direct for the same cost as CVS for out of pocket.
I was just thinking the same. (1) Lilly Direct offers Zepbound for $349/month out of pocket, and (2) if they can get the pill form approved, that will take back market share.
What did Novo Nordisk “pay” to get this position. Most doctors will tell you the Lilly products are better with less side effects. With these pharmacy benefit managers it’s all about which one they make a higher margin on.
I was thinking the same thing. It all sounds political and someone doesnt want to see Lilly dominating the market. A deal was brokered and this is the results. Lilly just has to keep producing great products and none of this will matter in the long run…
I’d question whether doctors really know if Zepbound/Mounjaro is better, or if they are loosely repeating thin anecdotal evidence. Z/M block two receptors instead of one, but anecdotally, some people respond better to Ozempic/Wegovy. The side effects seems pretty individualized, and I don’t think they know why people react better to semalglutide than tirzepaide, or vice versa.
I’m curious what else you know about this.
The drug market is so broken. Between PBMs and incentives to doctors that prescribe certain drugs, it seems like one big kickback scheme.
Agree